spacer
home > pmps > summer 2019 > serialising drugs to combat fraud
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Serialising Drugs to Combat Fraud

The worldwide pharmaceutical market is huge, estimated at over $1 trillion in 2016 (1). A growing portion of this is over-the-counter (OTC) medicines, which are projected to be worth $178 billion in 2024, driven by governments encouraging our ageing populations to check with their pharmacist before going to A&E to reduce the non-urgent load on hospitals (2).

An increasing number of patients are purchasing these OTC products online. Euromonitor estimates that despite only being 2% of sales in 2017, the speed at which this has grown in recent years has focused pharma companies’ attention, especially after Amazon quietly launched a line of OTC products in 2018 (3-4).

Unfortunately, buying pharmaceutical products online is fraught with issues; for example, it is estimated that a significant proportion of Viagra bought online is fake, and the side effects of counterfeit drugs can be fatal (5-6). Recently, the UK authorities seized a large amount of Diazepam, modafinil, and dermal fillers (7). The effect of poor dermal products can be life changing (8).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gillian Ewers is an experienced marketing professional with a track record of launching new products to market in hightech businesses. She brings a wealth of knowledge of delivering strategic roadmaps, marketing materials, and product lifecycle management across multiple sectors, including semiconductors and digital inkjet printing, at companies such as Texas Instruments, Dialog, CSR, and Xaar.
spacer
Gillian Ewers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization (CDMO), celebrates its 15th anniversary today. As a midsized CDMO, Northway Biotechpharma is able to provide flexibility and responsiveness backed by a strong foundation in science and technology. The company focuses on understanding its customers and meeting their specific needs without binding them to one single approach. It is able to react rapidly to unexpected project changes, adjusting timelines, capacities and other activities to meet its customers’ evolving needs. On average, Northway Biotechpharma has 25–30 development projects underway each year, ranging from gene cloning to final drug product manufacturing.
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

 
Industry Events

Event profile: PHARMAPACK 2020

6-7 February 2020,

Nemera will join more than 5,000 senior pharma professionals at Pharmapack, which will take place in Paris, on 5-6 February 2020. Meet Nemera at the booth C56 to discover its innovative drug delivery devices and its end-to-end development offerings! 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement